PATENT AB!STRACTS 287

or part of at least two distinct parental poly- peptides are disclosed. Such vectors are used in novel processes utilizing in viva recombination to produce recombined circular vectors con- taining said replicable DNA sequences and hybrid DNA sequences comprising: (1) a first DNA sequence encoding the amino-terminal portion of a hybrid polypeptide corresponding to a first part of a first parental polypeptide sequence and (2) a second DNA sequence encoding a carboxy-terminal portion of said hybrid polypeptide corresponding to a first part of a second parental polypeptide sequence. The hybrid DNA sequences of such recombined cir- cular vectors can exprress novel hybrid poly- peptides such as hybrid enzymes in general and in particular hybrid amylases and proteases. Various other processes are disclosed to isolate the recombined circular vector containing said hybrid DNA sequences.

SO93258

RECOMBINANT FOWLPOX VIRUS AND RECOMBINATION

VECTOR

Lawrence Cohen, Dennis L Panicali assigned to Therion Biologics Corporation

Recombinant fowlpox virus (FPV) capable of expressing immunogenic proteins of fowl patho- gens are described. The FPV express DNA of the pathogen under the direction of FPV promoters. The recombinant FPV provide live vaccines for poultry and other animals.

5993261

CANCER-RELATED ANTIGEN- SPECIFIC HUMAN

IMMUNOGLOBULINS AND HUMAN/HUMAN HYBRIDOMAS

HAVING THE ABILITY TO PRODUCE SAID HUMAN

IMMUNOGLOBULINS

Hideaki Hagiwara, Junzo Nagao, Kasai shi, Hyogo ken, Japan assigned to Hagiwara Yoshihid; Hagiwara Hideaki

A new human/human fused cell clone derived from human B cells having the ability to produce immunoglobulins and human B cells substan- tially lacking the ability to produce immuno- globulins, antigen-specific human immunoglobulins produced by the human/human fused cell clone, and a method of producing the human immunoglobulins. More

specifically, a human/human hybridoma having the ability to produce antigen-specific human immunoglobulins, which is a human/human fused cell strain derived from human B cells of a human patient with liver cancer and a subclone of a human lymphoblast cell strain; and antigen- specific human immunoglobulins produced by

the human/human fused cell strain.

5094945

INHIBITION RESISTANT 5- ENOLPYRUVYL 3-

PHOSPHOSHIKIMATE SYNTHASE, PRODUCTION AND

USE

Luca Comai assigned to Calgene Inc

Enhanced resistance to glyphosate, an inhibitor of the aromatic amino acid biosynthesis path- way, is imparted to a glyphosate sensitive host. A mutated aroA gene is employed which expresses 5-enolpyruvyl 3-phosphoshikimate synthase (EC: 2.5.1.19) (ES-3-P synthase). Methods are provided for obtaining the aroA mutation which provides the enzyme resistant to inhibition by glyphosate, means for introducing the structural gene into a sensitive host, as well as providing a method of producing the enzyme. The E. coli strain C600 (pPMG1) has been deposited at the A.T.C.C. on December 14, 1982 and given A.T.C.C. Accession No. 39256.

5095096

FUSED PROTEIN COMPRISING LYMPHOTOXIN

Tetsuzo Miki, Seishi Kato, Hiroshi Osada, Ab- iko, Japan assigned to Sagami Chemical Research Center; Central Glass Company Ltd ]Hodogaya Chemical Co Ltd INippon Soda Company Ltd INissan Chemical Industries Ltd ]Tosoh Corporati

A fused protein comprising a polypetide con- taining an antibody binding site of protein A and a polypeptide of lymphotoxin, and having bio- logical activities of lymphotoxin and an ability to bind to an antibody is disclosed. Further, a pro- cess for the production of the fused protein, as well as a DNA coding for the fused protein, a plasmid containing the DNA, and E. coli trans- formed with the plasmid, necessary for the above-mentioned process, are provided.